First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

Anna Schreiber(University of Colorado Anschutz Medical Campus), Jennifer R. Diamond(University of Colorado Cancer Center)

Cancers

December 23, 2023

10.3390/cancers16010091

Cited by 10

Related Papers

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

|Breast Cancer Research|2018|69

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

|Frontiers in Oncology|2017|22